Finally, the anti-tumor activity observed with exogenous CgA and VS-1 in the animal models suggest that pharmacological enhancement of circulating CgA and/or VS-1 in patients might represent potential therapeutic strategies that merit further investigation. The gene discussed is CGA; the disease is neoplasm.